The Epidemic
The number of people diagnosed with diabetes world-wide in the last 20 years has increased explosively and can now be considered as a diabetes “epidemic”. Long considered a disease of minor significance to world health, it is now viewed as a major threat to human health in the 21st century. The global incidence of the disease is set to rise from the current estimation of 150 million, to 220 million by 2010, and to 300 million by 2025. In developed countries the number of people with Diabetes will increase by 42% by 2025, while the increase in lesser developed countries is expected to be 170%. Diabetes used to occur mainly in middle age people, but today it is becoming very common in children.
Diabetes occurs when refined sugars are eaten too often and too fast, causing large swings in blood sugar levels. Although you don’t necessarily “feel” poor glucose levels, Diabetes reduces your quality of life because it causes so many other conditions that make you feel bad. Diabetes can lead to heart attacks, kidney and eye problems, and possible amputation of feet and legs over time.
The Solution
Emulin™ is a naturally derived compound that has the unique ability to “buffer” and “quelch” the effects of glucose on the human metabolic pathway which will be instrumental in treating hyperglycaemia and hopefully improve the lives of diabetics worldwide.
Emulin™ is an incredible discovery. It is a whole new way of attacking the problems of diabetes and metabolic syndrome, the precursor of diabetes. Metabolic Syndrome is a disorder of aging which is made up of five symptoms which are often seen together and predict diabetes.
These are;
1) Obesity – especially around the waist.
2) High blood pressure.
3) High cholesterol.
4) High triglycerides.
5) High fasting blood glucose levels.
These symptoms alert you to the fact that diabetes could be in your future if you don’t make some changes. Emulin™ should be one of them.
Emulin™ works by a combinational approach to mitigate the damage cause by hyperglycaemia from the diet by its insulinomimetic affects.
Emulin™ will:
* Reduce the dietary absorption of carbohydrates in the upper G.I.
* Reduce Glucose Synthesis in the Liver.
* Accelerate Glucose Uptake from the bloodstream.
* Mobilize carbohydrates (glucose) from adipocytes.
* Increase the sensitivity of Insulin receptors in the signalling pathways – this makes insulin more efficient.
Clinical Studies & Scientific Analysis
“ATM has gathered considerable experience in generating and applying Rational Drug Design and Computer Modeling... Continued computer simulations in conjunction with the pre-clinical and clinical results and data obtained from literature reviews, suggested that Emulin™, if consumed regularly, could not only have the acute effect of lowering the glycemic impact of foods, but chronically increase insulin production and sensitivity, lower background blood glucose levels of type 2 diabetics, and not only arrest, but reverse the development of diabetes in pre-diabetes individuals.”
Professor Dr. Ralph DeFronzo
Professor and Director & Division Chief, Diabetes Unit, University of Texas Health Center.
• Preclinical Trials
• 50 Diabetic Subjects Untreated With Insulin
• 10 Control Non Diabetic Subjects
• Glucose Levels Dropped By More Than 20%
• Glucose Levels Increased In Subjects Receiving Placebo
An independent study performed by Eurofins Product Safety Laboratories on diabetic rats treated with Emulin™ showed up to a 27 percent reduction in glucose levels. These results indicate that Emulin™ may have therapeutic potential in the management of both type 1 and type 2 diabetes.
“This is one of the most difficult and extreme research models to test with and I was very impressed with the outcome...I have never seen anything perform like this in this severe of a model, other than insulin itself...you may be regenerating B[eta]-cells”
Dr. Gary Grover, Principle Investigator
Professor of Physiology and Biophysics at Robert Wood Johnson Medical School and Director of Pharmacology for Eurofins.
Clinical Trials dgd Research Cetero Labs/Optimised Clinical Research
• 40 Type 2 Human Diabetic Subjects
• 10 Emulin™ / 10 leading diabetes Drug / 10 Placebo / 10 Drug + Emulin™
• Emulin™ Beat The Drug Significantly in Lowering Glucose
“Emulin™ does a better job at reducing blood sugar levels in type II diabetes than metformin, the most commonly prescribed drug. Emulin™...[is] a genuine breakthrough.”
Dr. Mark Kipnes
Executive Vice President, Associate Medical Director of dgd Cetero Labs
"At the end of one week, those subjects on placebo had a slight increase in fasting blood glucose levels, which continued into the second week... Those persons taking Emulin™ alone had an 11% decline at one week and a 20% decline by week 2".
Dr. Mark Kipnes
Executive Vice President, Associate Medical Director of dgd Cetero Labs